Archive for the ‘American Society of Hematology’ Category
Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting
ROCKVILLE, Md., Dec 06, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In an oral [...]
Posted on December 15, 2010 at 7:06 am by admin · Permalink
· Leave a comment
In: American Society of Hematology, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Leukemia & Lymphoma Society · Tagged with: American Society of Hematology, B-cell chronic lymphocytic leukemia, Emergent BioSolutions, Fuad El-Hibri, Hematology, Leukemia & Lymphoma Society, Non-Hodgkin lymphoma, Weill Medical College of Cornell University
In: American Society of Hematology, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Leukemia & Lymphoma Society · Tagged with: American Society of Hematology, B-cell chronic lymphocytic leukemia, Emergent BioSolutions, Fuad El-Hibri, Hematology, Leukemia & Lymphoma Society, Non-Hodgkin lymphoma, Weill Medical College of Cornell University
